Alternating intravenous and oral vinorelbine plus epirubicin with pegfilgrastim as neoadjuvant treatment of locally advanced breast cancer
| Autor: | Gian Paolo Biti, Fabiano Nosi, Roberto Santini, Simona Borghesi, Benedetta Agresti, Sergio Gavilli, Carla De Luca Cardillo, Fabiola Paiar, Alessandra Galardi, Dora Di Cosmo, Lorenzo Livi |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Oral
Adult Oncology Neoadjuvant treatment Infusions Cancer Research medicine.medical_specialty Filgrastim medicine.medical_treatment Breast cancer Oral chemotherapy Administration Oral Aged Antineoplastic Combined Chemotherapy Protocols Breast Neoplasms Epirubicin Female Granulocyte Colony-Stimulating Factor Humans Infusions Intravenous Middle Aged Neoadjuvant Therapy Recombinant Proteins Vinblastine Pharmacology Vinorelbine Polyethylene Glycols Internal medicine medicine Pharmacology (medical) Neoadjuvant therapy Chemotherapy business.industry medicine.disease Surgery Administration Intravenous business Pegfilgrastim medicine.drug |
| Zdroj: | Anti-Cancer Drugs. 17:1081-1085 |
| ISSN: | 0959-4973 |
| DOI: | 10.1097/01.cad.0000231478.22901.6e |
| Popis: | In order to downstage locally advanced breast cancer, neoadjuvant chemotherapy consisting of intravenous vinorelbine 25 mg/m plus epirubicin 75 mg/m given on day 1 and oral vinorelbine 60 mg/m on day 8 was administered every 3 weeks for four courses. On day 2, all patients received a single subcutaneous injection of pegfilgrastim (6 mg). From March 2004 to June 2005, 22 patients were enrolled. Patients characteristics were: median age, 53 years (range: 39-70 years); postmenopausal, 7/22; clinical TNM stage, T2 (n=14), T3 (n=8), N0 (n=17) and N1 (n=5). The median number of courses was four (range: two to six courses) with full dose intensity. National Cancer Institute grade 3 haematological toxicities observed were neutropenia in 9% of patients, anaemia in 13% of patients and thrombocytopenia in 9% of patients; no toxicity grade 4 occurred. Two patients (9%) registered grade 2 polyneuropathy; no cardiac failure was observed. Conservative surgery was performed in 14 patients (63%). All patients were evaluable for response: complete pathological response was documented in three patients (13.6%); three patients (13.6%) obtained more than 75% of tumour size reduction; 11 other patients (50%) had 50% of tumour size reduction; stable disease was observed in five patients (22.7%). The present findings indicate that vinorelbine in combination with epirubicin is an effective and safe treatment in locally advanced breast cancer: this regimen obtained more than 50% of tumour size reduction in 77% of patients; the use of pegfilgrastim allowed full dose intensity. Oral vinorelbine on day 8 offers greater convenience to the patient by reducing the need for intravenous injection and the time spent in hospital. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|